Aldeyra Therapeutics (ALDX) SC 13G Aldeyra Therapeutics, Inc.

Exhibit 99.1

JOINT FILING AGREEMENT

February 25, 2020

Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.

IN WITNESS WHEREOF, each party hereto, being duly authorized, has caused this agreement to be executed and effective as of the date first written above.

Date: February 25, 2020	PROSIGHT MANAGEMENT, LP
	By:	Prosight Partners, LLC
	Its:	General Partner
	By:	/s/ W. Lawrence Hawkins
	Name:	W. Lawrence Hawkins
	Title:	Sole Manager
	PROSIGHT FUND, LP
	By:	Prosight Management, LP
	Its:	General Partner
	By:	Prosight Partners, LLC
	Its:	General Partner
	By:	/s/ W. Lawrence Hawkins
	Name:	W. Lawrence Hawkins
	Title:	Sole Manager
	PROSIGHT PLUS FUND, LP
	By:	Prosight Management, LP
	Its:	General Partner
	By:	Prosight Partners, LLC
	Its:	General Partner
	By:	/s/ W. Lawrence Hawkins
	Name:	W. Lawrence Hawkins
	Title:	Sole Manager

PROSIGHT PARTNERS, LLC
By:	/s/ W. Lawrence Hawkins
Name:	W. Lawrence Hawkins
Title:	Sole Manager
W. LAWRENCE HAWKINS
/s/ W. Lawrence Hawkins